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Abstract
Background: This study protocol evaluates the effectiveness of adjuvant electroacupuncture (EA) for urinary
retention in poststroke patients undergoing conventional treatments, in comparison with that of a sham control.
Methods/design: A multicenter, blinded, randomized controlled trial will be conducted in three hospitals in the
Republic of Korea. We are recruiting 54 stroke survivors (aged >19 years), who were diagnosed with urinary
retention based on the results of two consecutive post-void residual (PVR) tests, and dividing them randomly into
two arms: the EA and Park-sham control groups.
They will receive ten sessions of EA or sham treatment for 2 weeks. The participants will be blinded with non-
penetrating needles and fake sounds of EA stimulators. The daily PVR ratio will be primarily measured at baseline
and at the end of the study to statistically test the effectiveness of EA for poststroke urinary retention. Then, the
Korean version of the Qualiveen Questionnaire, the Korean version of the International Prostate Symptom Score,
and the blinding index will be assessed. After each EA session or sham EA, adverse events will be reported to
evaluate the safety of EA.
Results will be analyzed by using the independent t-test or Mann-Whitney U test, based on both intention-to-treat
and per-protocol principles.
Discussion: The findings will provide clinical evidence for the effectiveness of EA treatment to improve urinary
retention in stroke survivors.
Trial Registration: This study protocol was registered in ClinicalTrials.gov (NCT02472288) on 10 June 2015.
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Background
Urinary retention (UR) or incomplete bladder emptying
(IBE), defined as a post-void residual (PVR) urine volume
of >100 mL on two consecutive occasions [1, 2], occurs in
approximately 29 % [1] to 56 % [3] of poststroke patients.
Bladder problems that occur after stroke episodes deteri-
orate the stroke survivors’ quality of life (QoL) and affect
their disability and mortality [4–6]. UR in stroke survivors
is usually managed with catheterization, but this proced-
ure interferes with their active rehabilitation and can in-
duce urinary tract infection (UTI) [2]. In the long term,
UR without adequate management can lead to renal dys-
function [7]. Thus, caregivers should provide poststroke
patients who have UR with proper bladder management
to improve the patients’ functional outcomes [8].
In the United Kingdom, sacral neurostimulation has
been known to be effective for UR induced by urethral
sphincter overactivity (Fowler’s syndrome). However,
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significant complications have occurred, such as inserted
lead migration or high surgical revision rates [9]. Bladder
problems have also been a concern of traditional medi-
cine practitioners. Diabetic bladder dysfunction was im-
proved with acupuncture treatment in a pilot study [10].
Another randomized controlled trial showed that, besides
sham electroacupuncture (EA), EA is an effective treat-
ment of bladder muscle overactivity in poststroke patients
[11]. A small-scale of clinical study with a single study
group suggested the potential benefit of EA therapy for
poststroke patients with IBE.
However, randomized controlled trials designed with
adequate statistical power and sham comparators should
be conducted to determine whether EA is effective for
poststroke UR. We will conduct a multicenter, random-
ized controlled trial to evaluate the effectiveness of adju-
vant EA therapy for poststroke patients with UR who
are undergoing conventional treatments, in comparison
with that of sham EA.
Methods/design
Study design
This is a multicenter, blinded, randomized controlled trial
to compare an EA group with a sham EA group, with an
allocation ratio of 1:1. We designed the protocol, conform-
ing to the Consolidated Standards of Reporting Trials
(CONSORT) [12] and Standards for Reporting Interven-
tions in Clinical Trials of Acupuncture (STRICTA) [13]
guidelines. The study process is illustrated in Fig. 1. The in-
stitutional review board of Kyung Hee University Korean
Medicine Hospital approved the study (KOMCIRB-
150213-HR-005). The protocol has been registered in
ClinicalTrial.gov (NCT02472288).
Fig. 1 Flowchart of the study process. Fifty-four participants will be randomized and allocated to either the intervention or control group. After
conducting ten sessions of verum or sham electroacupuncture for 2 weeks and examining for urinary tract infection (UTI), the daily post-void
residual (PVR) ratio, Korean version of Qualiveen Questionnaire score (K-QQ), Korean version of the International Prostate Symptom Score (K-IPSS),
and blinding index (BI) will be measured. Adverse events will be investigated right after each session
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Participants
We will recruit 54 male or female patients aged ≥19 years
from three hospitals in Korea: Kyung Hee Korean Medi-
cine Hospital in Seoul, Cheonan Korean Medicine Hospital
of Daejeon University in Cheonan, and Dongguk University
Ilsan Oriental Hospital in Ilsan. In order to identify survi-
vors from stroke episodes, like intracerebral hemorrhage or
cerebral infarction, experienced practitioners will check the
PVR urine volume twice a day. The patients will be
pre-screened only if both residual volumes are >100 mL.
After we obtain informed consent from the patients or
their representatives, we will screen them according to the
eligibility criteria for enrollment in the study.
Inclusion criteria
We will include both male and female patients aged
>19 years whose stroke episodes occurred within the last
2 years. We will not restrict inclusion of participants ac-
cording to type of stroke or damaged region in the brain.
Stroke history will be confirmed based on computed
tomography or magnetic resonance imaging examination
results. Two consecutive PVR tests will be performed,
and the patient with the results of both residuals >
100 mL will be included in the trial [1, 2].
Exclusion criteria
We will exclude stroke patients with any one of the fol-
lowing clinical conditions from the medical screening
process: (1) bleeding disorders, (2) procedures or surger-
ies for peripheral vascular diseases, (3) psychiatric disor-
ders, (4) severe diseases in the lower urinary tract, (5)
acute or chronic infectious diseases in the lower urinary
tract, or (6) pregnancy (laboratory results from urinaly-
sis). In addition, patients (7) whose medications for UR
or relevant symptoms (urinary incontinence drugs or
diuretics) have been changed within 3 days or (8) for
whom onset of treatment is within 1 week prior to the
study, along with those with a Glasgow Coma Scale score
of <8 points, will be excluded. Finally, we will also exclude
those who have fears about acupuncture therapy.
Dropout criteria
Patients will be removed from the study if they are un-
willing to continue their participation in the study. Pa-
tients who fail or anticipate to fail in continuing at least
seven sessions will be dropped from the study, too.
Randomization
Random sequences were generated separately in each
site with the R package (R Foundation for Statistical
Computing, Vienna, Austria, https://www.r-project.org)
to allocate participants into either the EA or sham
group. The allocation ratio was 1:1. From each center, at
least 14 participants will be recruited, and the last 12
persons will be competitively enrolled among all the
three sites. Only the delegated sub-investigators can ac-
cess the security electronic file of the randomization
table and assign the participants. Practitioners from each
site will call or send a message to the sub-investigators
in order to allocate the participants in their own hospitals.
After assignments are completed, a sub-investigator from
the primary site, Kyung Hee University Korean Medicine
Hospital, will allocate the 12 participants from the three
sites to the last participant. The investigators, who will
generate the random number and assignments, will be
blinded to the arm where each participant will be
allocated.
Blinding
The patients and outcome assessors will remain blinded
during the study. Patients assigned to the sham group
will undergo a similar treatment as those assigned to the
EA group. Because we will use the Park-sham with non-
penetrating acupuncture needles as control, electrosti-
mulation will be turned on without conductance. In
addition, we will use the same guide tubes used in the
Park-sham acupuncture needles in the intervention
group, too. Aside from the practitioners who will admin-
ister the EA or sham treatment, there will be an inde-
pendent outcome assessor who will not be notified
about the patients’ allocated arms.
Interventions
The EA and sham EA regimens are based on traditional
Korean medicine. We referred to the textbook [14] and
consulted acupuncture and stroke specialists.
The participants allocated to the EA group will receive
five sessions per week of EA therapy for 2 weeks (ten
sessions in total). After inserting needles (stainless steel,
0.25 mm in diameter and 4.0 mm in length; Dong Bang
Acupuncture Inc., Republic of Korea) using the Park-
sham guide tube on bilateral acupoints BL31, BL32, BL33,
and BL34 (eight points in total) at 5–10 mm in depth, the
de qi sensation is elicited. The locations of the acupoints
according to the World Health Organization Standard
Acupuncture Point Locations in the Western Pacific Re-
gion are illustrated in Fig. 2 [15]. De qi means an acupunc-
ture needle sensation of soreness, tingling, fullness, ache,
coolness, warmth, and heaviness, and a radiating sensation
at and around the acupoints to the point of a threshold
that elicits nerve impulse transmission to the cerebral cor-
tex [16]. Then, electrostimulation will be administered for
20 minutes at a moderate frequency of 30 Hz (STN-111,
Stratek, Republic of Korea).
We will use the Park-sham device in the control group.
The non-penetrating needles of the sham acupuncture
will be implemented on the same eight bilateral acupoints.
The total number of sessions of sham EA is ten (five times
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per week for 2 weeks). The electrostimulation will also be
administered for 20 minutes at moderate frequency (30 Hz;
STN-111, Stratek, Republic of Korea), even though the
stimulation will not be delivered through the skin because
of the non-penetrating needle of sham device.
The use of conventional therapies will be allowed
during the study for both groups. The conventional ther-
apies consist of general supportive care, preventive or
therapeutic management for medical/neurological compli-
cations, or drug treatments with antiplatelet agents,
anticoagulants, or neuroprotectants. Moreover, stroke
management with traditional herbal medications, acu-
puncture without electrostimulation, or rehabilitation for
stroke complications will be permitted during the trial.
However, any drugs, herbal medications, or rehabilitation
that could affect UR will be prohibited. The study will
Fig. 2 The locations of acupoints BL31, BL32, BL33, and BL34. In the sacral region, BL31, BL32, BL33, and BL34 are located in the first, second,
third, and fourth posterior sacral foramens, respectively. (World Health Organization Standard Acupuncture Point Locations in the Western
Pacific Region)
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conform to clinical practice guidelines for stroke manage-
ment in Korea [17].
Practitioners who have over 1 year of clinical experi-
ence will perform the EA or sham EA treatments.
Primary outcome
To evaluate the effectiveness of EA treatment over the
sham device for poststroke UR, we will primarily assess
the change in daily PVR urine ratios between the base-
line and end point of the last session. The daily PVR ra-
tio is computed by dividing the daily PVR urine volume
by the daily PVR urine volume plus spontaneous voiding
volume. The daily PVR urine volume for 24 hours will
be examined with ultrasonography scanning. If the PVR
urine volume is more than 100 mL, the residual will be
removed through intermittent cauterization before the
scanning. When spontaneous urination is impossible, a
24-hour weight change in diaper will be measured for
the self-voiding volume.
If the urinary tract is infected at the end, the outcome
assessor will measure the PVR urine volume on the third
day of the last session after anti-UTI treatment for
48 hours. Otherwise, PVR urine volume will be measured
on the next day of the last session.
Secondary outcome
Because UTI might affect the urine residuals [18, 19],
the patients in both groups will undergo urinalysis to de-
termine whether UTI exists before PVR urine volume
evaluation at the end point. UTI is diagnosed when ni-
trite is detected by urinalysis and two of the following
clinical symptoms exist: pyuria, lower abdominal pain,
or hematuria [20]. The urinalysis retest is performed
after 48 hours of antibiotics treatment.
We will also assess disease-specific QoL by using the
Korean version of the Qualiveen Questionnaire (K-QQ).
This is an assessment tool consisting of 30 items for pa-
tients with neurogenic bladder [21–24]. Each item, rated
from 0 to 4 points, evaluates patients’ bladder problems,
while the additive nine questions, rated from −2 to +2
points, are about patients’ general QoL status. The
higher the absolute value of the total K-QQ score, the
lower the QoL becomes. We will measure the K-QQ
scores at baseline and at the end of the last session.
The Korean version of the International Prostate
Symptom Score will be assessed at baseline and at the
end point. This scale is generally used to evaluate gen-
eral symptoms related to the lower urinary tract [25, 26].
The total score (0–35) is calculated by seven items of 0–5
points each, and the severity will be assessed as mild (0–7
points), moderate (8–19 points), or severe (20–35 points).
The frequencies of urination and urinary incontinence
will also be reported. The patients will record them by
urinary diary for 1 day before the first intervention and
for another day after the last intervention. The mean
change from posttreatment to pretreatment in the EA
group will be compared with that in the sham group.
Finally, we will measure the blinding index (BI) for all
of the participants at the end of the verum or the sham
EA. The success or failure of the participants’ blinding
will be assessed by using the validated scale [27]. The
outcome assessor will ask the participants where they
belong by selecting one of the following responses: “I
think I belonged to the EA group,” “I think I belonged
to the sham group,” or “I don’t know which group I
belonged to.”
The patient-rated outcomes will not be measured when
the participants are unconscious. The two caregivers with
more than 1 year of practical experience, after being edu-
cated about the scales, will independently fill in the scales
for the participants with low cognitive function and the
discrepancy will be settled through discussion.
Other outcomes
Information on diabetes mellitus (DM) and benign pros-
tatic hyperplasia (BPH) will be obtained from the partici-
pants’ medical history.
Safety assessment
Adverse events will be reported to evaluate the safety of
EA for poststroke patients with UR. The questionnaires
will be administered to the participants after every
verum or sham EA session, and the results will be re-
corded and analyzed. The outcome assessors will judge
the severity (mild, moderate, or severe), seriousness, and
causality (definitely related, probably related, possibly re-
lated, possibly not related, definitely not related to the
intervention, or not assessable).
Sample size
Based on a previous study [2], the mean percentage
change in PVR ratios in the EA and control groups were
computed. We assumed an after-treatment PVR ratio of
0.65 in the control group, as it was not reported in the
study. The null hypothesis was that the percentage
changes in PVR ratios have no significant difference be-
tween the intervention and control groups. With a sig-
nificance level of 0.05 and a statistical power of 0.8, the
calculated sample size in total was 42 [28]. Considering
a 20 % drop rate at a 1:1 allocation ratio, we will recruit
27 participants for each group.
Data analysis
We will analyze results primarily based on the principle
of intention - to - treat (ITT) and subordinately based
on the per - protocol (PP) principle. The ITT analysis
will include any participants who are randomly allocated
and have at least one EA or sham session. Missing
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values will be imputed by the last observation carried
forward. The PP analysis will cover only the patients
who have at least seven sessions of EA or sham treat-
ments and have no medical diagnosis of UTI at the end
point.
Continuous variables will be tested by the independent
t-test if normality is obtained. Otherwise, the Mann-
Whitney U test will be implemented. The categorical
variables will be analyzed by the Pearson χ2 test or Fish-
er's exact test.
Discussion
This randomized controlled trial aims to determine
whether EA treatment is effective for UR in poststroke
survivors. The effectiveness is represented by the relative
proportion of urine residuals and voiding volumes. Be-
cause this study is designed to provide clinical evidence
for the relevant patients and practitioners, we have
chosen not to eliminate any other general treatments for
poststroke survivors.
The eight acupoints were identified based on the
guideline published by the World Health Organization.
In the sacral region, BL31, BL32, BL33, and BL34 are
located in the first, second, third, and fourth posterior
sacral foramens, respectively [15]. In the literature on
traditional Korean medicine, these points have been re-
ported to possibly have the property to recover bladder
dysfunction, and they have shown clinical effectiveness
for poststroke detrusor overactivity in a previous study
[11]. The acupoints are considered to have a possible
mechanism that the acupuncture stimulation directly in-
creases the excitability of the pelvic nerve, which conse-
quently innervates the detrusor muscle [2].
Park-sham acupuncture is a placebo acupuncture de-
vice invented to stabilize the needle in position with an
additional guide tube preventing skin penetration [29].
This sham device was validated to be inactive and indis-
tinguishable [30]. We have decided to use the same
guide tubes as Park-sham acupuncture to prevent partic-
ipants from discovering the group to which they belong.
The apparatus for electrostimulation will be activated in
the sham control group to make the participants hear
the same machine sound so as to let them believe they
are under real acupuncture treatment. Because Park-
sham acupuncture does not intrude the skin, electrosti-
mulation will not be conducted through the body. Suc-
cess or failure of these blinding strategies will be
appraised at the end of the study by the BI [26].
Bladder dysfunction, including UR, poses an obstacle for
rehabilitation and QoL improvement in poststroke pa-
tients [2, 4–6]. Catheterization, the major therapeutic ap-
proach, confers the risk of UTI [2]. A preliminary clinical
study showed the potential benefits and safety of EA treat-
ment for stroke patients with UR [2]. However, the study
was performed only with a single group and lacked the
methodological requirements and statistical power to es-
tablish the evidence for treatment. Overall, clinical trials
of EA for any urinary dysfunction, with a placebo control,
are rare, except for the study of poststroke detrusor over-
activity [11]. We targeted UR in poststroke patients and
designed a randomized, sham-controlled trial to be con-
ducted in multiple sites to appropriately generalize the re-
sults of the trial, following the CONSORT [12] and
STRICTA guidelines [13].
At the end of the project, we expect that the findings
will provide clinical evidence of the effectiveness of EA
treatment for improving UR in stroke survivors.
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